SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory CD7+ hematolymphoid malignancies.
T-ALL|Lymphoma, T-Cell
BIOLOGICAL: SENL101
Safety: Incidence and severity of adverse events, The incidence and severity of adverse events and adverse reactions from infusion to withdrawal or before the safety follow-up period, 24 months post CAR-T cells infusion
Cytokine release, Changes from baseline in IFN-γ, TNF-α, IL-2, IL-6, IL-10, 12 months post CAR-T cells infusion|CD7 positive cells in peripheral blood at each time point, Absolute value and ratio of CD7 positive cells (T cells NK cells) at each time point in peripheral blood, 12 months post CAR-T cells infusion|T cell subsets, T cell subsets monitoring at each time point (CD4+ CD8+ CD4+/ CD8+ ratio), 12 months post CAR-T cells infusion|Immunogenicity endpoint, Detectable antibody concentration in serum at each time point, 12 months post CAR-T cells infusion|T cell NK cell recovery time after treatment, Absolute value of T cells NK cells at each time point, 12 months post CAR-T cells infusion
Main research purposes:

To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory CD7+ hematolymphoid malignancies.

Secondary research purposes:

To preliminarily evaluate the efficacy, pharmacokinetics and pharmacodynamics of SENL101 in the treatment of patients with relapsed or refractory CD7+ hemolymphoid malignancies.

Exploratory research purpose：

1. To explore the immunogenicity of SENL101；
2. T cell NK cell recovery time after treatment；
3. Other indicators of interest to researchers。